Stock Pick

  • Pro Medicus signs A$25m US contract: What it means for investors

    Health professional working on his laptop.

    The Pro Medicus Ltd (ASX: PME) share price is on watch today after the company announced a new 7-year, A$25 million contract with Valley Health in the United States, covering its full suite of cloud-based medical imaging solutions.

    What did Pro Medicus report?

    • Signed a 7-year, A$25 million contract with Valley Health in the U.S.
    • Valley Health will implement Visage 7 Viewer, Workflow, Open Archive and Cardiology Imaging
    • Contract to be delivered using a cloud-based, transaction-based pricing model
    • Migrating Valley Health’s legacy PACS archive to Visage 7 Open Archive
    • Go-live implementation target set for Q1 of calendar year 2027

    What else do investors need to know?

    The Valley Health contract continues Pro Medicus’ momentum in the North American market, expanding its reach in the Mid-Atlantic region. This deal showcases the company’s growing reputation for delivering unified, cloud-based imaging solutions.

    Importantly, Valley Health chose to adopt the full range of Visage 7 products, including the cardiology module—reflecting ongoing industry trends toward platform consolidation and cloud adoption. With its flexible, transaction-based pricing, Pro Medicus may also see further upside as usage grows.

    What did Pro Medicus management say?

    Pro Medicus CEO, Dr Sam Hupert, commented:

    Valley Health provides award-winning care to their patients and is committed to improving the health of their region. They join our established customers in Virginia and the Mid-Atlantic, reflecting an ever-growing list of Visage 7 clients opting for our fully cloud-based platform, which, as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.

    What’s next for Pro Medicus?

    Planning for the Valley Health rollout will commence immediately, with go-live aimed for the first quarter of 2027. The company expects continued growth from its ‘Full Stack +1’ offering, catering to health enterprises looking to modernise and unify their imaging systems.

    With a strong pipeline across all segments and growing demand in North America, Pro Medicus appears well placed to build on its position as a leading provider of cloud-based medical imaging software.

    Pro Medicus share price snapshot

    Over the past 12 months, the Pro Medicus share price has underperformed the S&P/ASX 200 index (ASX: XJO) with a disappointing decline of around 33%.

    View Original Announcement

    The post Pro Medicus signs A$25m US contract: What it means for investors appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Pro Medicus right now?

    Before you buy Pro Medicus shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    See the 5 Stocks

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

  • Elevra Lithium share price on watch amid new long-term Mangrove supply deal

    A man checks his phone next to an electric vehicle charging station with his electric vehicle parked in the charging bay.

    The Elevra Lithium Ltd (ASX: ELV) share price is in focus today after the lithium miner announced a binding supply agreement with Mangrove Lithium for long-term spodumene concentrate supply, featuring a price floor above production costs and no ceiling on potential pricing upside.

    What did Elevra Lithium report?

    • Signed a 7-year binding Spodumene Concentrate Supply Agreement with Mangrove Lithium, with a further 7-year renewal option
    • Year 1 contracted volume: 122,000 dry metric tonnes (dmt); Year 2 onwards: 144,000 dmt per annum, take or pay
    • Agreement includes a price floor above North American Lithium (NAL) production costs, and no price ceiling
    • Performance subject to Mangrove Lithium achieving final investment decision (FID) by 31 December 2028
    • Both Elevra and Mangrove have received investment support from the Canada Growth Fund

    What else do investors need to know?

    The agreement secures Elevra a stable, long-term local customer for its Québec-based NAL production, reducing exposure to volatile seaborne shipping costs and providing more predictable margins. This collaboration also strengthens Elevra’s presence in the North American lithium market, aligning with Canadian government initiatives to build a domestic battery supply chain.

    Deliveries to Mangrove’s planned Eastern Canada conversion facility support a regional mine-to-chemicals supply chain. The agreement allows for flexible contracted volumes and further optional purchases before commercial operation, providing additional upside if Mangrove scales faster.

    What did Elevra Lithium management say?

    Elevra’s Chief Executive Officer and Managing Director, Lucas Dow, said:

    This binding agreement with Mangrove Lithium is a significant step forward from the MoU we announced. It provides Elevra with a long-term local customer for NAL production on attractive terms, backed by a price floor set above our expected cost of production and with no price ceiling to limit potential upside. Supplying a customer located close to NAL also allows us to avoid the seaborne freight costs associated with shipping to international customers, which further supports our margins.

    We are pleased that both Elevra and Mangrove Lithium have separately attracted the support of the Canada Growth Fund. That shared backing is a strong signal of the Canadian government’s commitment to building a domestic lithium supply chain.

    What’s next for Elevra Lithium?

    Looking ahead, Elevra Lithium will work with Mangrove as it seeks financing and final approval for the Canadian conversion facility. If all conditions are met, Elevra will benefit from consistent local demand and protection against downside price risk while remaining exposed to upside in global spodumene prices.

    This agreement fits Elevra’s strategy of growing its North American presence and supporting the development of regional battery manufacturing infrastructure. Investors can watch for progress updates as Mangrove advances toward final investment decision and commercial operations.

    Elevra Lithium share price snapshot

    The Elevra Lithium share price has smashed the S&P/ASX 200 index (ASX: ELV) over the past 12 months with a whopping gain of approximately 130%.

    View Original Announcement

    The post Elevra Lithium share price on watch amid new long-term Mangrove supply deal appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Elevra Lithium right now?

    Before you buy Elevra Lithium shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Elevra Lithium wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    See the 5 Stocks

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

  • BSP Financial Group earnings: Profit and revenue up for H1 2026

    a couple getting financial advice from a consultant

    The BSP Financial Group Ltd (ASX: BFL) share price is in focus after the bank reported first-half 2026 statutory net profit after tax of K619.9 million, up 8.4%, and revenue of K1.89 billion, an increase of 17.7%.

    What did BSP Financial Group report?

    • Revenue: K1.89 billion (A$620.2 million), up 17.7% on the prior corresponding period
    • Net profit after tax: K619.9 million (A$203.9 million), up 8.4%
    • Interim dividend: K0.54 per share, up 8.0%
    • Cost to income ratio: 43.8%, within the 42-45% guidance range
    • Capital adequacy ratio: 25.3%, comfortably above regulatory requirements
    • Return on equity (ROE): 23.9%

    What else do investors need to know?

    BSP Financial Group highlighted ongoing investment in its ‘Modernising for Growth’ program, resulting in higher employment costs and technology upgrades. The business continues to grow its lending portfolio and enhance digital offerings, while also expanding financial inclusion initiatives like the BSP Wantok Wallet, now used by over 278,000 customers.

    During the half, BSP became the exclusive banking partner for the 2026 Rugby League World Cup. The company also announced plans for a new purpose-built headquarters in Port Moresby, aiming to support future growth and establish a significant commercial presence in Papua New Guinea’s capital.

    What did BSP Financial Group management say?

    Group Chief Executive Officer Mark T. Robinson said:

    Our strong first-half performance reflects the success of our diversified business, ongoing investment in our growth strategy, and the dedication of our people.

    What’s next for BSP Financial Group?

    Management shared an optimistic medium-term outlook, buoyed by a pipeline of major resource projects in Papua New Guinea and the South Pacific. However, BSP noted short-term risks such as the impact of El Niño on agriculture and resources output.

    The company is focused on implementing its multi-year Modernising for Growth program, continuing to invest in technology, customer service, and community initiatives, while maintaining prudent capital management to support lending and shareholder returns.

    BSP Financial Group share price snapshot

    Over the past 12 months, BSP Financial shares have risen 5%, trailing the All Ordinaries Index (ASX: XAO), which has been flat over the same period.

    View Original Announcement

    The post BSP Financial Group earnings: Profit and revenue up for H1 2026 appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Bsp Financial Group right now?

    Before you buy Bsp Financial Group shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Bsp Financial Group wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    See the 5 Stocks

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Latest

Sorry, but nothing was found. Please try a search with different keywords.